Over 24% of Indian adults across all states are now considered overweight or obese with more than 12.5 million children under ...

Wegovy-maker Novo Nordisk presented new data on Wednesday showing its experimental weight-loss pill improved blood sugar ...

The Company’s investigational small moleculeglucagon-like peptide-1 (“GLP-1”) receptor agonist (“RA”), BMF-650, demonstrated potent weight loss ...

A new international study has found that a diabetes pill called oral semaglutide can help protect the heart. This medication, ...

Semaglutide reduces the risk of heart attack, stroke, and other major cardiac events. | Drug Discovery And Development ...

New clinician-guided program blends medical science, microdosing, and 24/7 support to make advanced weight loss and wellness ...

A new observational study compared the risk for severe gastrointestinal adverse events across dulaglutide, semaglutide, and ...

In 2023, 48.5 million people ages 12 or older in the U.S. contended with a substance use disorder or disorders -- for almost 29 million, it was an alcohol use disorder (AUD) and around 27 million ...

Tirzepatide, semaglutide, and liraglutide vs DPP4i were associated with lower risk of alcohol use disorder, especially among men and younger patients.

The SOUL trial, published in the New England Journal of Medicine, tracked 9,650 adults with type 2 diabetes and elevated cardiovascular risk over nearly four years.

The FDA has approved Rybelsus, the first oral GLP-1 receptor agonist, to reduce cardiovascular risk in type 2 diabetes ...

Some guys are getting this promising new weight loss drug on the grey market. Here's what it does and the risks of taking it ...